Tim Anderson
Stock Analyst at B of A Securities
(3.19)
# 1,074
Out of 5,163 analysts
50
Total ratings
51.85%
Success rate
2.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Neutral | $220 → $221 | $241.52 | -8.50% | 10 | Jan 22, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,286 → $1,268 | $985.08 | +28.72% | 2 | Dec 15, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $105 → $120 | $115.61 | +3.80% | 5 | Dec 15, 2025 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Buy | $52 → $61 | $59.08 | +3.25% | 2 | Dec 15, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $543 → $627 | $745.77 | -15.93% | 3 | Oct 29, 2025 | |
| PFE Pfizer | Maintains: Neutral | $28 → $30 | $26.58 | +12.87% | 3 | Oct 3, 2025 | |
| AMGN Amgen | Maintains: Underperform | $261 → $272 | $366.21 | -25.73% | 6 | Sep 26, 2025 | |
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $71.90 | +21.00% | 1 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $5.09 | +391.16% | 3 | Aug 28, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $204 | $219.68 | -7.14% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $116 → $126 | $144.99 | -13.10% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $41 → $34 | $52.56 | -35.31% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $181.55 | -1.96% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $153.44 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $189.90 | - | 1 | Sep 22, 2017 |
Johnson & Johnson
Jan 22, 2026
Maintains: Neutral
Price Target: $220 → $221
Current: $241.52
Upside: -8.50%
Eli Lilly and Company
Dec 15, 2025
Maintains: Buy
Price Target: $1,286 → $1,268
Current: $985.08
Upside: +28.72%
Merck & Co.
Dec 15, 2025
Maintains: Buy
Price Target: $105 → $120
Current: $115.61
Upside: +3.80%
Bristol-Myers Squibb Company
Dec 15, 2025
Upgrades: Buy
Price Target: $52 → $61
Current: $59.08
Upside: +3.25%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Underperform
Price Target: $543 → $627
Current: $745.77
Upside: -15.93%
Pfizer
Oct 3, 2025
Maintains: Neutral
Price Target: $28 → $30
Current: $26.58
Upside: +12.87%
Amgen
Sep 26, 2025
Maintains: Underperform
Price Target: $261 → $272
Current: $366.21
Upside: -25.73%
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $71.90
Upside: +21.00%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $5.09
Upside: +391.16%
AbbVie
Apr 28, 2025
Maintains: Neutral
Price Target: $200 → $204
Current: $219.68
Upside: -7.14%
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $144.99
Upside: -13.10%
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $52.56
Upside: -35.31%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $181.55
Upside: -1.96%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $153.44
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $189.90
Upside: -